Three-Tier Legislation Governing Medical Devices in New Zealand

1. Key takeaways

The New Zealand medical device system consists of three layers: one Act and two sets of regulations. The Act layer is the Medicines Act 1981 (1981 No 118); the regulation layers are the Medicines Regulations 1984 (SR 1984/143) and the Medicines (Database of Medical Devices) Regulations 2003 (SR 2003/325). All three are administered by the Ministry of Health, and Medsafe officially states it administers all three.

The division of labour is clear. The Act layer answers the origin questions, what a medical device is and that devices must be safe; the 1984 Regulations govern post-market conduct (labelling, advertising, false compliance claims, recall orders); the 2003 Regulations govern the database and notification and are the sole establishment basis of WAND (Web Assisted Notification of Devices). GRZAN’s verification repeatedly confirmed three boundaries where errors occur.

First, the statutory device definition exists only at the Act layer, in s 3A of the Medicines Act 1981; the 1984 Regulations contain no device definition clause. Second, the notification duty exists only in the 2003 Regulations; the 1984 Regulations contain no WAND, database or notification provisions, and hanging the duty off the 1984 Regulations is a mis-citation. Third, none of the three layers requires approval, licence or registration before supply. Medsafe’s homepage describes lawful supply as requiring notification to WAND, but SR 2003/325 sets no prohibition on sale without notification; force lies in the time-limit duties of reg 6 (notification within 30 working days) and reg 8 (correction within 10 working days), breaches under reg 14 fined up to NZ$500; and on Medsafe’s reading notification runs from the day the device first arrives in New Zealand, after arrival rather than as a premarket precondition.

The instruments span 22 years (1981 Act, 1984 Regulations, 2003 Regulations), yet the terminology is interconnected: reg 3 of the 2003 Regulations provides that medical device and Director-General carry the same meaning as in the Medicines Act 1981. Do not read the three layers as isolated rule sets.

2. Legal basis

The table sets out the three layers with official numbers, key dates and device-relevant provisions.

Authorising chain: both regulation sets were made under s 105 of the Medicines Act 1981 (Part 3 advertising of the 1984 Regulations additionally under s 62). Paragraphs (e)–(l) of s 105 authorise regulations on import, export, manufacture, packaging, labelling, storage, sale and supply of devices, their withdrawal from the market, licensing and supervision of premises, designation of kinds of devices, standards of composition and performance accuracy, and labelling manner and content.

3. Expert insights

Insight 1: All three layers share one authorising source, so definitions must be cross-referenced. Reg 3 of the 2003 Regulations points medical device, Director-General, practitioner and registered health professional to the Act-layer definitions. Whether a product is a device is therefore always answered in s 3A and s 4 of the Act, never in either regulation set. The classic GRZAN error: searching the 2003 Regulations for a device definition and the 1984 Regulations for the notification duty, finding neither, and concluding notification is voluntary.

Insight 2: What the 1984 Regulations do not contain matters more than what they do. The 1984 Regulations act on devices through post-market conduct control, a negative conclusion with high practical value: no device definition clause, no WAND clause, no notification clause, no database clause. Citing SR 1984/143 as requiring device notification is a mis-attribution.

Insight 3: The two sets of regulations sit about 6 years apart in current-version dates, reflecting where reform landed. The current version of the 2003 Regulations is 7 August 2020; the 1984 Regulations and the Act are both at 10 July 2026. Recent legislative activity concentrates at the Act layer: the Medicines Amendment Act 2025 (2025 No 66, assent 18 November 2025, in force 19 November 2025) inserted ss 22A–22F, a medicines verification pathway. GRZAN’s verification of the Ministry of Health’s February 2026 briefing, Regulatory settings for medical devices, confirms it applies only to medicines, not to medical devices.

Insight 4: There is no approval layer between the three layers. The Act layer supplies the safety floor (s 38: a device must be safe for its intended purpose); the regulation layers supply notification (reg 6 of the 2003 Regulations) and conduct rules (the 1984 Regulations). No step grants the regulator power to review technical documentation and approve market entry. Medsafe is equally explicit: WAND is not an approval system, and notification does not mean Medsafe has assessed quality, safety, effectiveness or performance.

4. Practical recommendations

• Build an internal three-layer mapping table and file provisions by layer. GRZAN recommends tagging every device duty as Act-layer, 1984 Regulations or 2003 Regulations, recording official number, commencement date and provision alongside. The mapping eliminates errors such as attributing notification to the 1984 Regulations and is reusable in training and audit responses.
• Proceed in the order: Act-layer characterisation, 2003 Regulations notification, 1984 Regulations conduct rules. First characterise with s 3A and s 4; second, if the product is a device outside the Schedule 1 exemptions, notify under regs 5, 6 and 7 of the 2003 Regulations; third, check reg 12(4) labelling and regs 10, 11 and 25 advertising of the 1984 Regulations. GRZAN fixes this order in deliverables to cut missed cross-references.
• Always cite official numbers in external documents. Use Medicines Act 1981 (1981 No 118), Medicines Regulations 1984 (SR 1984/143) and Medicines (Database of Medical Devices) Regulations 2003 (SR 2003/325), avoiding unofficial labels such as New Zealand device act that create verification difficulties.
• Run version monitoring on two tracks. The 2003 Regulations have not been amended since August 2020; the Medical Products Bill that would replace the Act had not been introduced to Parliament as at the verification date, Parliament adjourned on 24 September 2026 and dissolved on 1 October 2026, with the election set for 7 November 2026, and no timetable version is confirmed, so it should not drive production planning (a practical estimate).

5. Verification checklist

• □ Product characterisation is based on s 3A and s 4 of the Act, not on either regulation set
• □ Notification is based on regs 5 and 6 of the 2003 Regulations (SR 2003/325)
• □ Labelling and advertising are based on reg 12(4), reg 10, reg 11 and reg 25 of the 1984 Regulations (SR 1984/143)
• □ No internal document mis-attributes notification to the 1984 Regulations
• □ Numbers, dates and current versions of all three instruments are recorded item by item with the verification date
• □ Medical Products Bill statements are marked as not introduced as at the verification date, a policy draft
• □ Nowhere is WAND notification described as registration, approval or certification

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the New Zealand market. Our team manages Medsafe sponsor obligations and WAND entry requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com